Investigators at Brigham and Women’s Hospital led the first study that offers national data on the factors that may increase the risk of complications or death in critically ill COVID-19 patients. David E. Leaf, MD, MMSc and Shruti Gupta, MD, MPH, physicians in the Brigham’s Division of Renal Medicine, led a team of more than 300 investigators from over 65 hospitals across the U.S. to examine the demographics, comorbidities, organ dysfunction, treatment and outcomes of patients with COVID-19 admitted to intensive care units (ICUs). Read More
In March of 2020, Mass General Brigham (MGB) implemented a universal masking policy that required all staff in the health care system to wear a surgical mask while in the hospital. MGB is comprised of 78,000 employees across 12 Massachusetts-based hospitals, including Brigham and Women’s Hospital and Massachusetts General Hospital (MGH).
The Injection Molded Autoclavable, Scalable, Comfortable (iMASC) system developed by bioengineers and clinicians at Brigham and Women’s Hospital.
At Brigham and Women’s Hospital, the biomedical research lab of Giovanni Traverso, MB, BChir, PhD recently developed a new reusable, scalable alternative to N95 masks, which have been in short supply within healthcare settings during the COVID-19 pandemic.
While COVID-19 primarily affects the lungs of those infected, many patients have reported a wide range of unusual neurological symptoms. These include headaches, altered mental status, strokes, seizures and loss of smell. Many researchers have hoped that autopsies could shed light on the unknowns of COVID-19, caused by the novel coronavirus SARS-CoV-2.
From 7T MRI performed at Brigham and Women’s Hospital in Study Patient 1. This is a T2* gradient-echo sequence (0.8 mm isotropic voxels) showing a typical MS lesion (arrow) as oval, and bright, containing a central (dark) vessel.
During the COVID-19 pandemic, patients with multiple sclerosis (MS) and their clinicians have had questions and concerns about whether immunotherapies for MS could influence risk for infection or lead to an unfavorable outcome.
Remdesivir has emerged as a promising therapeutic candidate for the treatment of COVID-19 due to its ability to inhibit pathogenic animal and human coronaviruses, including severe acute respiratory syndrome 2 (SARS-CoV-2) and Middle East Respiratory Syndrome coronavirus (SARS-CoV-1).
SARS-CoV-2 and influenza A (H1N1) are in the same category of virus and both infect the respiratory tract. However, research has shown distinctive vascular changes in the lungs of patients with COVID-19 compared to those with H1N1.
Early reports of the COVID-19 outbreak in Wuhan, China included evidence of coagulation abnormalities in some patients. Since then, studies have shown an increase in venous thromboembolism (VTE)—including deep vein thrombosis (DVT) and pulmonary embolism (PE)—in some patients with COVID-19. Higher rates of incidence have been observed in patients in the intensive care unit (ICU) than in other hospitalized COVID-19 patients.
At Brigham and Women’s Hospital, nephrologists have observed an increased risk of acute kidney injury (AKI) in COVID-19 patients. Within the intensive care units (ICUs) at the Brigham, about 15 to 20 percent of COVID-19 patients have developed AKI. In some hospitals, the incidence of AKI has been reported to be as high as 25 percent.
Despite being highly contagious, a significant portion of people infected with COVID-19 don’t experience any symptoms. Those people who do exhibit symptoms most commonly experience dry cough, fever and difficulty breathing. However, there are also a myriad of atypical symptoms that may be under-reported.